[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
November 2013

Fundus Autofluorescence Is Not the Best Early Screen for Hydroxychloroquine Toxicity—Reply

Author Affiliations
  • 1Department of Ophthalmology, University of California, San Francisco
  • 2Gorovoy Eye Specialists, Fort Myers, Florida

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2013;131(11):1488. doi:10.1001/jamaophthalmol.2013.5077

In Reply We agree fully with the comments from Dr Marmor, whom we consider the leading authority regarding hydroxychloroquine maculopathy. A bull’s-eye should never be seen if patients are well screened, as it signifies advanced disease.

These images were intended to remind ophthalmologists that hydroxychloroquine maculopathy still exists, especially when patients have been poorly followed up or overdosed. In preventive medicine, however, the question of discontinuation of hydroxychloroquine often places the health care practitioner who is screening for soft signs of early toxic effects in the difficult position of discontinuing an excellent and systemically safe drug vs risking irreversible vision loss from toxicity. Confirmatory tests such as autofluorescence and multifocal electroretinography may facilitate the decision on whether to observe or stop the medication.